- Home
- CPRI vs GH Comparison
CPRI vs GH Comparison
Compare CPRI & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPRI | GH |
|---|---|---|
| Founded | 1981 | 2011 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 13.3B |
| IPO Year | 2011 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CPRI | GH |
|---|---|---|
| Price | $17.96 | $93.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 19 |
| Target Price | $26.50 | ★ $121.11 |
| AVG Volume (30 Days) | ★ 2.6M | 1.6M |
| Earning Date | 02-03-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $4,442,000,000.00 | $982,021,000.00 |
| Revenue This Year | N/A | $33.40 |
| Revenue Next Year | $1.86 | $28.32 |
| P/E Ratio | $15.22 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $11.86 | $36.36 |
| 52 Week High | $28.27 | $120.74 |
Technical Indicators
Market Signals| Indicator | CPRI | GH |
|---|---|---|
| Relative Strength Index (RSI) | 43.43 | 54.63 |
| Support Level | $16.88 | $89.32 |
| Resistance Level | $22.29 | $103.16 |
| Average True Range (ATR) | 0.77 | 4.24 |
| MACD | 0.11 | 1.39 |
| Stochastic Oscillator | 50.10 | 82.24 |
Price Performance
Historical ComparisonAbout CPRI Capri Holdings Limited
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.